Showing 1341-1350 of 2874 results for "".
- Access to Care and Hispanic Cultural Attitudes Regarding Epilepsyhttps://practicalneurology.com/news/access-to-care-and-hispanic-cultural-attitudes-regarding-epilepsy/2469772/Research on attitudes and perceptions toward health care amongst diverse groups of people is required to address social determinants of health that lead to health care disparities in the US. Findings from virtual focus groups of people with epilepsy, living in Texas and California and reporting M
- Perampanel as Monotherapy or First Adjunctive Therapy Effectively Reduced Seizures in a Phase 4 Studyhttps://practicalneurology.com/news/perampanel-as-monotherapy-or-first-adjunctive-therapy-effectively-reduced-seizures-in-a-phase-4-study/2469771/In the ELEVATE study (NCT03288129), 63% (34/54) of individuals, age 4 or more, who were treated with perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) as monotherapy or a first adjunctive therapy continued treatment over a 12-month period. The retention rate was higher when perampanel was used as m
- Efgartigimod Treatment Improves Function for People With Generalized Myasthenia Gravishttps://practicalneurology.com/news/efgartigimod-treatment-improves-function-for-people-with-generalized-myasthenia-gravis/2469618/Efgartigimod (Argenx, Boston, MA) vs placebo treatment of acetylcholine receptor-antibody positive (antiAChR+) generalized myasthenia gravis (gMG) resulted in clinical improvement for 67.7% vs 29.7% of those treated (P<.0001). Activities of daily living were measured with the M
- New No-Cost Course for Professionals in Stroke Centers with High-Volume of COVID-19https://practicalneurology.com/news/new-no-cost-course-for-professionals-in-stroke-centers-with-high-volume-of-covid-19/2469417/The American Heart Association is offering an education course for healthcare professionals on stroke care with considerations for additional protocols and care practices that come with the COVID-19 pandemic. This course is made possible by support from the Leona B. and Harry M. H
- Tauroursodeoxycholic Acid /Sodium Phenylbutyrate Decreased Rate of Decline in ALShttps://practicalneurology.com/news/tauroursodeoxycholic-acid-sodium-phenylbutyrate-decreased-rate-of-decline-in-als/2469369/Results of a pivotal phase 2/3 clinical trial (NCT03127514) evaluating tauroursodeoxycholic acid (TUDCA) /sodium phenylbutyrate (PB) combination (AMX0035; Amylyx Pharmaceuticals, Cambridge, MA) for treatment of amyotrophic lateral sclerosis (ALS) has been published in the New England Journal of M
- Research Leaders Recognized at the 2025 MDA Clinical & Scientific Conferencehttps://practicalneurology.com/news/research-leaders-recognized-at-the-2025-mda-clinical-scientific-conference/2473814/The Muscular Dystrophy Association (MDA) recognized 2 legacy award recipients at the 2025 MDA Clinical & Scientific Conference. The awardees were honored based on their significant contributions to clinical research and community advocacy. The 2025 MDA Legacy Award for Achie
- MDA Provides COVID-19 Recommendations for People with Neuromuscular Conditions that Also Apply to Other Neurologic Conditionshttps://practicalneurology.com/news/mda-provides-covid-19-recommendations-for-people-with-neuromuscular-conditions-that-also-apply-to-other-neurologic-conditions/2469188/The Muscular Dystrophy Association (MDA) has provided recommendations for people in the neuromuscular community regarding the current COVID-19 pandemic. Noting that current guidelines from public health agencies focus on travelers, specific age group
- Studies Evaluate the Reweighting of Parkinson Disease Assessment Tools for Improved Sensitivity and Efficiencyhttps://practicalneurology.com/news/studies-evaluate-the-reweighting-of-parkinson-disease-assessment-tools-for-improved-sensitivity-and-efficiency/2474181/Reweighting the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and other measures may provide greater sensitivity and responsiveness in assessing motor and functional decline in people with Parkinson disease (PD), according to the results of 2 studies presented at
- Continuous, Subcutaneous Apomorphine Infusion Device Approved for Parkinson’shttps://practicalneurology.com/news/continuous-subcutaneous-apomorphine-infusion-device-approved-for-parkinsons/2473778/The Food and Drug Administration (FDA) has approved the wearable Onapgo (apomorphine hydrochloride; Supernus Pharmaceuticals, Rockville, MD) subcutaneous injection device to treat motor fluctuations in adults with advanced Parkinson disease (PD). Onapgo enables continuous apomorphine infusion dur
- National Institutes of Health Allege Research Misconduct by Prominent Neuroscientist and Investigator of α-Synuclein in PD and ADhttps://practicalneurology.com/news/nih-alleges-research-misconduct-by-prominent-neuroscientist-and-investigator-of-a-synuclein-in-pd-and-ad/2470601/Eliezer Masliah, MD, director of the National Institutes of Aging (NIA) neuroscience division, has been accused of research misconduct via the falsification, duplication, and manipulation of images, particularly western blot images. Much of Dr. Masliah’s work focuses on the role of &al